The Cannabis Company That Won't Mix Work With Pleasure
A limited supply of cannabis in the U.S. means those resources have to be divvied up carefully.
For Cronos Group, that means keeping its medical and recreational marijuana operations in completely different verticals, CEO Michael Gorenstein told Cheddar. That ensures patients’ needs are prioritized over those of recreational users.
“If you think about building a town, and you have a limited amount of building supplies, we want to make sure that we’re building a hospital before we’re building the bar,” he said.
Canada-based Cronos Group started trading on the NASDAQ on Tuesday, making it the first marijuana company to list on a major U.S. market.
“It’s a big milestone not just for us but for the entire industry,” said Gorenstein. “[It] just continues to show the acceptance that the cannabis industry is getting.”
And the industry does seem to be growing at break-neck speed. Arcview, a leading researcher of the cannabis market, stated in a [recent report](https://arcviewgroup.com/product/5th-edition/) that the industry brought in $9.7 billion in sales in 2017, and that number could grow to over $25 billion by 2021.
For the full interview, [click here](https://cheddar.com/videos/inside-the-first-cannabis-company-to-list-on-nasdaq).
Ben Soffer, aka @boywithnojob, discusses his journey from social media influencer to entrepreneur and why he wanted to enter the competitive drink space. Watch!
StockstoTrade.com Technical Trainer, Tim Bohen, discusses why he thinks Trump is doing what he is doing and how it will affect the market going forward.
Jacob Sonenshine, Stock Pick Writer at Barron's, unpacks the current state of the markets, Trump's tariffs and if more volatility is on the way. Watch!
RedFin's Chen Zhao joins Cheddar to breakdown the current state of the housing market in the United States and what prospective homebuyers need to know. Watch!
